Reena Khanna


Contact Information

London Health Sciences Centre-University Campus
339 Windermere Road
London, ON, Canada N6A 5A5
Tel: 519.685.8500 ext. 34945
Fax: 519.663.3700

Research Interests/Specializations

The development of outcome measures for evaluation of new treatments for IBD and designing and conducting clinical trials.

Dr. Reena Khanna is the Assistant Dean, Clinical Research Training at Western University. She is also an Associate Professor in the Departments of Medicine and Biostatistics & Epidemiology Western University. She completed her MD and Internal Medicine residency at the University of Western Ontario, Gastroenterology fellowship at McMaster University. Dr. Khanna completed an advanced fellowship in inflammatory bowel disease (IBD) at the Cleveland Clinic, followed by a research fellowship in international IBD clinical trials at the University of Western Ontario. She completed an MSc in clinical epidemiology at McMaster University. Her clinical and research interests are clinical trial design, new therapeutics, outcome measures. She has designed, conducted and published several studies, including the first cluster study in IBD. Dr. Khanna holds international grants and was awarded the Crohn’s Colitis Canada’s rising star award for her research contributions.

Selected Publications

Afif W, Sattin B, Dajnowiec D, Khanna R, Seow CH, Williamson M, Karra K, Wang Y, Gao LL, Bressler B. Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Dig Dis Sci, 2021 Aug 17; online ahead of ePub (online), Coauthor

Ricciuto A, Carman N, Benchimol EI, Siddiqui I, Putra J, Khanna R, Griffiths AM, Walters TD, Church PC. Prospective Evaluation of Endoscopic and Histologic Indices in Pediatric Ulcerative Colitis Using Centralized Review. Am J Gastroenterol. 2021 Aug 13; online ahead of ePub (online), Coauthor

Cheah M, Wilson A, Solh Z, Khanna R. IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab. Inflamm Bowel Dis, 2021 May 18, Senior Responsible Author, DOI: 10.1093/ibd/izab090.

Ma C, Khanna R, Guizzetti L, Zou G, Feagan BG, Jairath V. Methods for handling missing segments in Crohn’s disease clinical trials: analysis from the EXTEND trial. Gut, 2021 May 6, Coauthor, DOI: 10.1136/gutjnl-2021-324658.

Khanna R, Afif W. Ustekinumab for Ulcerative colitis. Gastroenterology, 2021 Feb 3, Principal Author, DOI: 10.1053/j.gastro.2021.02.002.

Townsend CM, Khanna R, Wilson AS. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists. Dig Dis Sci, 2021 Jan 11, Coauthor, DOI: 10.1007/s10620-020-06773-7.

Almradi A, Ma C, D’Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. An expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials. Aliment Pharmacol Ther, 2021 Jan 7, Coauthor, DOI: 10.1111/apt.16248.

Casteele NV, Abreu MT, Flier S, Papamichael K, Rieder F, Silverberg MS, Khanna R, Okada L, Yang L, Jain A, Cheifetz AS. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol, 2021 Jan 6, Coauthor, DOI: 10.1016/j.cgh.2021.01.006.

Khanna R, Ma C, Jairath V, Casteele NV, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol, 2020 Dec 15, Principal Author, DOI: 10.1016/j.cgh.2020.12.017.

Khanna R, Zhou GY, Afif W. Comparative Efficacy Trials in Inflammatory Bowel Disease. Gastroenterology, 2020 Jul 15, Principal Author, DOI: 10.1053/j.gastro.2020.07.009.

Ayoub A, Jairath V, Aldraiweesh S, Khanna R, Gregor J, Chande N. Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series. Inflamm Bowel Dis, 2020 Jul 11, Coauthor, DOI: 10.1093/ibd/izaa182.

Dulai PS, Jairath V, Zou G, Stitt LW, Khanna R, Sandborn WJ, Feagan BG, Singh S. Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. Inflamm Bowel Dis, 2020 Jun 27, Coauthor, DOI: 10.1093/ibd/izaa168.

Khanna R, McCurdy J, Afif W. Pharmacokinetics of TNF antagonists. Gastroenterology, 2020 May 17, Principal Author, DOI: 10.1053/j.gastro.2020.05.040.

Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG. Adalimumab for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev, 2020 May 16; 5: CD012877, Coauthor, DOI: 10.1002/14651858.CD012877.pub2.

Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis, 2020 May 12; 26 (6): 949-959, Coauthor, DOI: 10.1093/ibd/izz244. 

Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. Development of the symptoms and impacts questionnaire for Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther, 2020 Apr 21, Coauthor, DOI: 10.1111/apt.15726.

Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2020 Jan 27; 1: CD012381, Coauthor, DOI: 10.1002/14651858.CD012381.pub2.

Ma C, Smith M, Guizzetti L, Panaccione R, Kaplan GG, Novak KL, Lu C, Khanna R, Feagan BG, Singh S, Jairath V, Ananthakrishnan AN. Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). Clin Gastroenterol Hepatol, 2020 Jan 24, Coauthor, DOI: 10.1016/j.cgh.2020.01.023.

Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastroenterol, 2020 Jan 4, Senior Responsible Author, DOI: 10.1007/s11938-019-00259-w.

Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O’Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context, 2020 Jan 1; 9, Coauthor, DOI: 10.7573/dic.2020-2-1.